HHHui Huang

Hui Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Huang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sono‐Tribocatalytic Whole Tumor Cell Vaccine Enables Ultrasound‐Controlled Immune Boosting for Enhanced Anti‐Tumor Immunity

    by Hongze Ren, Qingying Wu, Wei Yang, Zhengqi Tang, Lili Xia, Chenyao Wu, Xinyue Dai, Hui Huang, Yu Chen

    Whole tumor cell vaccines are uniquely positioned for personalized immunotherapy by presenting the full repertoire of tumor‐associated antigens to counter tumor heterogeneity, yet their translation is persistently hindered by poor immunogenicity and the requirement for multiple administrations. Herein, we introduce a sono‐tribocatalytic vaccine platform by integrating MnVO 3 nanosheets into tumor cells, enabling ultrasound‐controlled immune boosting following a single vaccination. Upon a single subcutaneous injection, non‑invasive ultrasound irradiation triggers intense interfacial friction between the nanosheets and surrounding tissue fluids, driving efficient generation of reactive oxygen species via triboelectric charge transfer and concurrent release of metal ions that orchestrate metal‑immune crosstalk. This unique sono‑tribocatalytic process establishes a spatiotemporally remote control of localized inflammation to function as an on‐demand “sono‐booster.” Mechanistically, this sono‐booster reprograms the local immune microenvironment by amplifying oxidative stress and inflammatory signaling, thereby promoting dendritic cell maturation and antigen cross‑presentation to elicit antigen‑specific T cell responses. Remarkably, a single dose of this sono‑tribocatalytic vaccine achieves potent anti‐tumor efficacy across multiple preclinical models. By enabling on‑demand, non‑invasive immune boosting from a single injection through a sono‑tribocatalytic mechanism, this vaccine platform establishes an externally controllable strategy for enhancing vaccine‐induced immunity and offers a versatile framework for next‐generation cancer immunotherapy.

  • Sono‐Tribocatalytic Whole Tumor Cell Vaccine Enables Ultrasound‐Controlled Immune Boosting for Enhanced Anti‐Tumor Immunity

    by Hongze Ren, Qingying Wu, Wei Yang, Zhengqi Tang, Lili Xia, Chenyao Wu, Xinyue Dai, Hui Huang, Yu Chen

    Whole tumor cell vaccines are uniquely positioned for personalized immunotherapy by presenting the full repertoire of tumor‐associated antigens to counter tumor heterogeneity, yet their translation is persistently hindered by poor immunogenicity and the requirement for multiple administrations. Herein, we introduce a sono‐tribocatalytic vaccine platform by integrating MnVO 3 nanosheets into tumor cells, enabling ultrasound‐controlled immune boosting following a single vaccination. Upon a single subcutaneous injection, non‑invasive ultrasound irradiation triggers intense interfacial friction between the nanosheets and surrounding tissue fluids, driving efficient generation of reactive oxygen species via triboelectric charge transfer and concurrent release of metal ions that orchestrate metal‑immune crosstalk. This unique sono‑tribocatalytic process establishes a spatiotemporally remote control of localized inflammation to function as an on‐demand “sono‐booster.” Mechanistically, this sono‐booster reprograms the local immune microenvironment by amplifying oxidative stress and inflammatory signaling, thereby promoting dendritic cell maturation and antigen cross‑presentation to elicit antigen‑specific T cell responses. Remarkably, a single dose of this sono‑tribocatalytic vaccine achieves potent anti‐tumor efficacy across multiple preclinical models. By enabling on‑demand, non‑invasive immune boosting from a single injection through a sono‑tribocatalytic mechanism, this vaccine platform establishes an externally controllable strategy for enhancing vaccine‐induced immunity and offers a versatile framework for next‐generation cancer immunotherapy.

  • Open Access

    Lysosomal zinc nanomodulation blocks macrophage pyroptosis for counteracting atherosclerosis progression

    by Ruizhi Hu, Junchang Qin, Wei Feng, Xinran Song, Hui Huang, Chen Dai, Bo Zhang, Yu Chen

    Macrophage pyroptosis has been identified as a critical pathological mechanism in inflammation-related atherosclerosis (AS). In this work, we have demonstrated that Zn 2+ features the strongest anti-inflammatory performance by screening 10 representative metal ions, and the MTC1 agonists can trigger lysosomal Zn 2+ release and inhibit pyroptosis in macrophages. Based on these findings, we further engineered a mucolipin TRP channel 1 (MTC1)–related therapeutic nanoplatform for endogenously triggering lysosomal zinc release to curb inflammation and block macrophage pyroptosis. This nanoplatform consists of mesoporous silica nanoparticles to deliver MTC1 agonists and carbon nanodots, which could synergistically exert antiatherosclerotic effect by scavenging toxic reactive oxygen species, inhibiting macrophage pyroptosis, modulating macrophage transition, and rebuilding atherosclerotic immune microenvironment. These findings demonstrate that macrophage pyroptosis can be efficiently blocked via leveraging self-lysosomal zinc pool, which provides the paradigm of lysosomal zinc modulation-involved nanotherapeutics for managing other inflammatory diseases.


  • Open Access

    Single-atom–doped piezocatalyst induces copper-free cuproptosis in tumor therapy

    by Meixiang Zhang, Xinran Song, Yu Qin, Yuanyuan Peng, Shanshan Zhang, Wei Feng, Hui Huang, Yu Chen, Jianqiao Zhou

    Cuproptosis, a distinct cell death pathway, has been integrated into nanomedicine for disease theranostics. However, current nanosystems inducing cuproptosis rely on exogenous toxic copper ions, limiting the scope of biomaterials. Developing nanoplatforms that induce cuproptosis without exogenous copper holds substantial promise. Here, we engineered a two-dimensional iron (Fe) single-atom–doped molybdenum disulfide (MoS 2 ) piezocatalyst (Fe-MoS 2 ) for tumor therapy. Incorporating single Fe atoms enhances MoS 2 piezoelectric polarization via charge redistribution and modulates Fe and Mo oxidation states, enabling multifaceted enzymatic activities, including peroxidase-, glutathione oxidase–, oxidase-, and catalase-like activities. Upon ultrasound stimulation, the Fe-MoS 2 nanocatalyst generates reactive oxygen species and depletes glutathione via synergistic piezocatalytic and enzyocatalytic effects, disrupting copper ion homeostasis and inducing cuproptosis, concurrently triggering ferroptosis and ferritinophagy, which collectively enhances tumor suppression. This study represents the first paradigm to introduce a copper-free piezocatalyst for initiating cuproptosis, substantially advancing the applications of cuproptosis in tumor therapy.